UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009795
Receipt number R000011475
Scientific Title Preliminary investigation of contrast media dose for sequential diagnosis of cerebral MR perfusion and 3D-MR DSA at 3T MRI
Date of disclosure of the study information 2013/04/01
Last modified on 2022/08/05 11:30:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Preliminary investigation of contrast media dose for sequential diagnosis of cerebral MR perfusion and 3D-MR DSA at 3T MRI

Acronym

Sequential diagnosis of cerebral MR perfusion and 3D-MR DSA at 3T MRI

Scientific Title

Preliminary investigation of contrast media dose for sequential diagnosis of cerebral MR perfusion and 3D-MR DSA at 3T MRI

Scientific Title:Acronym

Sequential diagnosis of cerebral MR perfusion and 3D-MR DSA at 3T MRI

Region

Japan


Condition

Condition

Brain tumor

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To preliminarily investigate imaging protocol of sequential MRI examination of perfusion MRI and 3D-MR DSA by reducing dose (Magnevist) in each imaging at 3T MRI.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase IV


Assessment

Primary outcomes

Conduct a qualitative assessment of Perfusion MRI and 3DMR DSA

Key secondary outcomes

CNR of gray matter and white matter
SNR of gray matter and white matter
Adverse drug reaction to the contrast agent


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

3

Purpose of intervention

Diagnosis

Type of intervention

Medicine

Interventions/Control_1

Preliminary investigate possibility of reducing half dose (0.05mmol/kg) in perfusion MRI and 3D-MR DSA, respectively. And comparing single dose(0.1mmol/kg) with half dose. Secondly, investigate dose proportion of sequential MRI.

Interventions/Control_2

Preliminary investigate possibility of reducing half dose (0.05mmol/kg) in perfusion MRI and 3D-MR DSA, respectively. And comparing single dose(0.1mmol/kg) with half dose. Secondly, investigate dose proportion of sequential MRI.

Interventions/Control_3

Preliminary investigate possibility of reducing half dose (0.05mmol/kg) in perfusion MRI and 3D-MR DSA, respectively. And comparing single dose(0.1mmol/kg) with half dose. Secondly, investigate dose proportion of sequential MRI.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Suspect brain tumor pts or follow up of brain tumor
2) Over 20 years old
3) Accept regardless of gender
4) Clear consciousness

Key exclusion criteria

1) Contraindication of MRI
2) Allergy to Gd contrast media
3) Asthma
4) Severe renal disease
5) During pregnancy or lactation
6) Investigator make a judgmental decision as unsuitableness

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Keigo
Middle name
Last name Shimoij

Organization

Juntendo Univ.

Division name

Department of Radiology

Zip code

113-8421

Address

Hongo 2-1-1, Bunkyo-ku, Tokyo 111-8421

TEL

03-3813-3111

Email

kshimoji@juntendo.ac.jp


Public contact

Name of contact person

1st name Keigo
Middle name
Last name Shimoji

Organization

Juntendo Univ.

Division name

Department of Radiology

Zip code

113-8421

Address

Hongo 2-1-1, Bunkyo-ku, Tokyo 111-8421

TEL

03-3813-3111

Homepage URL


Email

kshimoji@juntendo.ac.jp


Sponsor or person

Institute

Juntendo Univ.

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo Univ IRB

Address

Hongo 2-1-1, Bunkyo-ku, Tokyo 111-8421

Tel

03-5802-1584

Email

chiken@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2012 Year 12 Month 11 Day

Date of IRB

2013 Year 03 Month 31 Day

Anticipated trial start date

2013 Year 04 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 01 Month 17 Day

Last modified on

2022 Year 08 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011475


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name